GSK (GSK) expects 2025 turnover growth of between 6% to 7%, previously towards the top end of the range of between 3% to 5%; Core operating profit growth of between 9% to 11%, previously towards the top end of the range of between 6% to 8%; and Core EPS growth of between 10% to 12%; previously towards the top end of the range of between 6% to 8%.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK reports Q3 core EPS 55p, up 14% at CER
- Cautious Outlook on GlaxoSmithKline: Sell Rating Amid Anticipated Revenue Declines and Market Challenges
- Cautious Outlook on GlaxoSmithKline Despite Strong Financial Performance: Sell Rating Due to Market Headwinds and Modest Guidance Upgrades
- GSK’s LUNELORD Study: New Insights into Lupus Nephritis
- Scynexis price target lowered to $3 from $4 at Guggenheim